|
Patient characteristics at the index date and mortality in the following 6 months |
||
| Cases (%) |
Controls (%) |
|
|
|
||
| Number of patients |
1,090 |
44,990 |
| Mean age at index date ± SD |
74.1 ± 5.7 |
71.1 ± 4.3 |
| Number of patients 66–74 |
670 (61.5) |
36,900 (82.0) |
| Number of patients 75–84 |
369 (33.9) |
7,665 (17.0) |
| Number of patients ≥ 85 |
51 (0.05) |
425 (0.9) |
| Risk factors |
||
| Mammography in years 2 or 3 prior to the index date |
514 (47.2) |
35,229 (78.3) |
| History of diagnostic and therapeutic breast procedures in the 3 prior to the index date |
19 (1.7) |
296 (0.7) |
| Benign neoplasm of the breast in the 3 years prior to the index date |
15 (1.4) |
319 (0.7) |
| Other breast disease in the 3 years prior to the index date |
169 (15.5) |
4,667 (10.4) |
| Estrogen replacement therapy in the year prior to the index date |
299 (27.4) |
17,837 (39.7) |
| Combined estrogen/progesterone therapy in the year prior to the index date |
101 (9.3) |
4,943 (11.0) |
| Visit to a gynecologist in the year prior to the index date |
152 (13.9) |
10,076 (22.4) |
| Exposure to the drugs of interest (one or more prescriptions in the year prior to the index date) |
||
| Ns-NSAID/COX-2 inhibitors |
443 (40.6) |
22,126 (49.2) |
| Ns-NSAIDs |
102 (9.4) |
5,572 (12.4) |
| COX-2 inhibitors |
388 (35.8) |
19,228 (42.7) |
| Rofecoxib |
242 (22.2) |
11,498 (25.6) |
| Celecoxib |
203 (18.6) |
10,269 (22.8) |
| Aspirin |
329 (30.2) |
13,391 (29.8) |
| Acetaminophen |
253 (23.2) |
10,159 (22.6) |
| Not exposed* |
375 (34.4) |
12,260 (27.3) |
|
SD – standard deviation *Not exposed refers to the group of patients who were not exposed to ns-NSAIDs, aspirin, COX-2 inhibitors or acetaminophen during the year prior to the index date | ||
Rahme et al. BMC Cancer 2005 5:159 doi:10.1186/1471-2407-5-159 |
||